R
REVELATION BIOSCIENCES, INC.
REVBCIK 0001810560NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.90M
Total Assets
$11.58M
Equity
$8.90M
Shares Out
3.72M
Op. Cash Flow
$-8.27M
Business
REVELATION BIOSCIENCES, INC. is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary Gemini formulation. It develops therapeutic candidates based on Gemini (a PHAD/MPLA TLR4 agonist) to modulate innate immunity. Its main product programs include Gemini-AKI for prevention of acute kidney injury, Gemini-CKD for treatment of chronic kidney disease, and Gemini-PSI for prevention or treatment of post-surgical infection. The company conducts preclinical and clinical development, relies on third-party manufacturing, and pursues U.S. and international commercialization through partners, licensing and regulatory approvals.
Summary from filing dated 2025-03-06
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 4 | 4 | 5 | 7 | |
| General and administrative | 5 | 4 | 5 | 5 | 5 | |
| Total operating expenses | 9 | 8 | 9 | 11 | 12 | |
| Loss from operations | −9 | −8 | −9 | −11 | −12 | |
| Change in fair value of warrant liability | 2,158 | 81,441 | 8 | 0 | 1 | |
| Other income (expense), net | 155,007 | −7 | 207,473 | 34,962 | −36,352 | |
| Total other income (expense), net | 157,165 | −7 | 9 | 34,962 | −36,352 | |
| Net loss | −9 | −15 | −120,254 | −11 | −12 | |
| Deemed dividends | −6 | — | — | — | — | |
| Net loss attributable to common stockholders | −15 | −15 | — | — | — | |
| Net loss per share, basic | −23.95 | −1,052 | −8.44 | −149.2 | −42.5 | |
| Net loss per share, diluted | −23.95 | −1,052 | −8.44 | −149.2 | −42.5 | |
| Weighted-average shares used to compute net loss per share, basic | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 | |
| Weighted-average shares used to compute net loss per share, diluted | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 6 | 12 | 5 | — | |
| Prepaid expenses and other current assets | 111,297 | 66,699 | 84,691 | 73,132 | — | |
| Total current assets | 11 | 7 | 12 | 5 | — | |
| Property and equipment, net | 18,067 | 56,332 | 65,084 | 90,133 | — | |
| Operating lease right-of-use asset | 722,288 | 0 | — | — | — | |
| Other assets | 30,941 | 0 | — | — | — | |
| Total assets | 12 | 7 | 12 | 6 | — | |
| Accounts payable | 577,501 | 783,621 | 1 | 554,205 | — | |
| Accrued expenses | 1 | 1 | 1 | 985,497 | 2 | |
| Operating lease liability | 23,013 | 0 | — | — | — | |
| Total current liabilities | 2 | 2 | 6 | 4 | — | |
| Operating lease liability, net of current portion | 723,771 | 0 | — | — | — | |
| Total liabilities | 3 | 2 | 6 | 4 | — | |
| Commitments and Contingencies (Note 4) | — | — | — | — | — | |
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,584 | 44 | 16 | 77 | — | |
| Additional paid-in-capital | 58 | 45 | 32 | 26 | — | |
| Accumulated deficit | −49 | −41 | −25 | −25 | — | |
| Total stockholders' equity | 9 | 5 | 7 | 1 | — | |
| Total liabilities and stockholders' equity | 12 | 7 | 12 | 6 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 595,368 | 168,850 | 155,721 | 301,116 | 470,878 | |
| Depreciation expense | 27,058 | 27,923 | 25,049 | 25,048 | 16,782 | |
| Non-cash lease expense | 18,630 | — | 0 | 14,960 | 52,384 | |
| Loss on disposal of equipment | 11,207 | — | — | — | — | |
| Issuance of common stock for services | — | 25,000 | — | — | — | |
| Prepaid expenses and other current assets | −44,598 | 17,992 | −11,559 | 569,044 | −509,342 | |
| Deferred offering costs | — | 71,133 | 82,071 | −61,154 | — | |
| Other assets | −30,941 | — | — | — | — | |
| Accounts payable | −206,120 | −576,277 | 749,660 | −666,042 | −269,640 | |
| Accrued expenses | 269,756 | −3 | 161,963 | −592,987 | 1 | |
| Operating lease liability | 5,866 | — | 0 | −16,752 | −50,592 | |
| Net cash used in operating activities | −8 | −18 | −7 | −11 | −11 | |
| Purchase of property and equipment | — | −19,171 | — | — | −131,963 | |
| Net cash used in investing activities | — | −19,171 | — | — | −131,963 | |
| Net cash provided by financing activities | 12 | 13 | 14 | 15 | 8 | |
| Net increase (decrease) in cash and cash equivalents | 4 | −5 | 7 | 4 | −3 | |
| Deemed dividend for exercise price reductions of warrants | 6 | — | — | — | — | |
| Operating lease right-of-use asset exchanged for lease liability | 740,918 | — | — | — | 67,344 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro